{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T09:15:24Z","timestamp":1778058924861,"version":"3.51.4"},"reference-count":40,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Computational Biology and Chemistry"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.compbiolchem.2022.107768","type":"journal-article","created":{"date-parts":[[2022,9,7]],"date-time":"2022-09-07T12:39:50Z","timestamp":1662554390000},"page":"107768","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"special_numbering":"C","title":["Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant"],"prefix":"10.1016","volume":"104","author":[{"given":"Mohnad","family":"Abdalla","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Amgad M.","family":"Rabie","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"9","key":"10.1016\/j.compbiolchem.2022.107768_bib1","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.3390\/pharmaceutics13091400","article-title":"Combination Therapy with Fluoxetine and the Nucleoside Analog GS-441524 Exerts Synergistic Antiviral Effects against Different SARS-CoV-2 Variants In Vitro","volume":"13","author":"Brunotte","year":"2021","journal-title":"Pharmaceutics"},{"issue":"10","key":"10.1016\/j.compbiolchem.2022.107768_bib2","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1016\/j.eng.2020.03.007","article-title":"Experimental Treatment with Favipiravir for COVID-19: An Open-Label Control Study","volume":"6","author":"Cai","year":"2020","journal-title":"Engineering"},{"issue":"11","key":"10.1016\/j.compbiolchem.2022.107768_bib3","doi-asserted-by":"crossref","first-page":"4690","DOI":"10.1021\/acs.jproteome.0c00392","article-title":"Nucleotide Analogues as Inhibitors of SARS-CoV-2 Polymerase, a Key Drug Target for COVID-19","volume":"19","author":"Chien","year":"2020","journal-title":"J. Proteome Res."},{"issue":"1","key":"10.1016\/j.compbiolchem.2022.107768_bib4","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1186\/s12967-020-02476-9","article-title":"A painful lesson from the COVID-19 pandemic: the need for broad-spectrum, host-directed antivirals","volume":"18","author":"Chitalia","year":"2020","journal-title":"J. Transl. Med."},{"issue":"12","key":"10.1016\/j.compbiolchem.2022.107768_bib5","doi-asserted-by":"crossref","first-page":"5588","DOI":"10.1080\/07391102.2021.1871956","article-title":"In silico study indicates antimalarials as direct inhibitors of SARS-CoV-2-RNA dependent RNA polymerase","volume":"40","author":"Doharey","year":"2022","journal-title":"J. Biomol. Struct. Dyn."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib6","unstructured":"DrugDevCovid19. RdRp. Available from: \u3008http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=RdRp&id=P0DTD1\u3009 (last Accessed 2\u00a0August 2022a)."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib7","unstructured":"DrugDevCovid19. Nsp14. Available from: \u3008http:\/\/clab.labshare.cn\/covid\/php\/database_target.php?target=nsp14&id=P0DTD1\u3009 (last Accessed 2\u00a0August 2022b)."},{"issue":"20","key":"10.1016\/j.compbiolchem.2022.107768_bib8","doi-asserted-by":"crossref","first-page":"6151","DOI":"10.3390\/molecules26206151","article-title":"In Silico Exploration of Potential Natural Inhibitors against SARS-Cov-2 nsp10","volume":"26","author":"Eissa","year":"2021","journal-title":"Molecules"},{"issue":"2","key":"10.1016\/j.compbiolchem.2022.107768_bib9","doi-asserted-by":"crossref","first-page":"E162","DOI":"10.1073\/pnas.1718806115","article-title":"Structural and molecular basis of mismatch correction and ribavirin excision from coronavirus RNA","volume":"115","author":"Ferron","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"7819","key":"10.1016\/j.compbiolchem.2022.107768_bib10","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41586-020-2368-8","article-title":"Structure of replicating SARS-CoV-2 polymerase","volume":"584","author":"Hillen","year":"2020","journal-title":"Nature"},{"issue":"19","key":"10.1016\/j.compbiolchem.2022.107768_bib11","doi-asserted-by":"crossref","first-page":"5795","DOI":"10.3390\/molecules26195795","article-title":"Discovery, Development, and Patent Trends on Molnupiravir: A Prospective Oral Treatment for COVID-19","volume":"26","author":"Imran","year":"2021","journal-title":"Molecules"},{"issue":"1","key":"10.1016\/j.compbiolchem.2022.107768_bib12","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1186\/s12879-021-05773-w","article-title":"Hydroxychloroquine in the treatment of outpatients with mildly symptomatic COVID-19: a multi-center observational study","volume":"21","author":"Ip","year":"2021","journal-title":"BMC Infect. Dis."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib13","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2020.104857","article-title":"A library of nucleotide analogues terminate RNA synthesis catalyzed by polymerases of coronaviruses that cause SARS and COVID-19","volume":"180","author":"Jockusch","year":"2020","journal-title":"Antiviral Res."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib14","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2021.174233","article-title":"Efficacy and safety of dihydroorotate dehydrogenase (DHODH) inhibitors \"leflunomide\" and \"teriflunomide\" in Covid-19: a narrative review","volume":"906","author":"Kaur","year":"2021","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib15","doi-asserted-by":"crossref","DOI":"10.3389\/fmicb.2021.647693","article-title":"Combining SARS-CoV-2 Proofreading Exonuclease and RNA-Dependent RNA Polymerase Inhibitors as a Strategy to Combat COVID-19: a High-Throughput in silico Screening","volume":"12","author":"Khater","year":"2021","journal-title":"Front. Microbiol."},{"issue":"8","key":"10.1016\/j.compbiolchem.2022.107768_bib16","doi-asserted-by":"crossref","first-page":"4593","DOI":"10.1073\/pnas.071050798","article-title":"Immucillin H, a powerful transition-state analog inhibitor of purine nucleoside phosphorylase, selectively inhibits human T lymphocytes","volume":"98","author":"Kicska","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113233","article-title":"Advance of structural modification of nucleosides scaffold","volume":"214","author":"Lin","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib18","doi-asserted-by":"crossref","first-page":"n2713","DOI":"10.1136\/bmj.n2713","article-title":"Covid-19: Pfizer\u2019s paxlovid is 89% effective in patients at risk of serious illness, company reports","volume":"375","author":"Mahase","year":"2021","journal-title":"BMJ"},{"issue":"9","key":"10.1016\/j.compbiolchem.2022.107768_bib19","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2106379119","article-title":"Structure and dynamics of SARS-CoV-2 proofreading exoribonuclease ExoN","volume":"119","author":"Moeller","year":"2022","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"12","key":"10.1016\/j.compbiolchem.2022.107768_bib20","doi-asserted-by":"crossref","first-page":"1346","DOI":"10.2174\/1389450121999201202110303","article-title":"Remdesivir (GS-5734) in COVID-19 Therapy: The Fourth Chance","volume":"22","author":"Moirangthem","year":"2021","journal-title":"Curr. Drug Targets"},{"key":"10.1016\/j.compbiolchem.2022.107768_bib21","unstructured":"PubChem. Riboprine. PubChem CID: 24405, available from \u3008https:\/\/pubchem.ncbi.nlm.nih.gov\/compound\/Riboprine\u3009 (last Accessed 14\u00a0August 2022)."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib22","doi-asserted-by":"crossref","DOI":"10.1016\/j.crphar.2021.100055","article-title":"Teriflunomide: A possible effective drug for the comprehensive treatment of COVID-19","volume":"2","author":"Rabie","year":"2021","journal-title":"Curr. Res. Pharmacol. Drug Discovery"},{"key":"10.1016\/j.compbiolchem.2022.107768_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.intimp.2021.107831","article-title":"Cyanorona-20: The first potent anti-SARS-CoV-2 agent","volume":"98","author":"Rabie","year":"2021","journal-title":"Int. Immunopharmacol."},{"issue":"2","key":"10.1016\/j.compbiolchem.2022.107768_bib24","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1039\/D0NJ03708G","article-title":"Two antioxidant 2,5-disubstituted-1,3,4-oxadiazoles (CoViTris2020 and ChloViD2020): successful repurposing against COVID-19 as the first potent multitarget anti-SARS-CoV-2 drugs","volume":"45","author":"Rabie","year":"2021","journal-title":"New J. Chem."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2021.109480","article-title":"Potent toxic effects of Taroxaz-104 on the replication of SARS-CoV-2 particles","volume":"343","author":"Rabie","year":"2021","journal-title":"Chem.-Biol. Interact."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib26","doi-asserted-by":"crossref","DOI":"10.1016\/j.molstruc.2021.131106","article-title":"Discovery of Taroxaz-104: The first potent antidote of SARS-CoV-2 VOC-202012\/01 strain","volume":"1246","author":"Rabie","year":"2021","journal-title":"J. Mol. Struct."},{"issue":"3","key":"10.1016\/j.compbiolchem.2022.107768_bib27","doi-asserted-by":"crossref","first-page":"2960","DOI":"10.1021\/acsomega.1c05998","article-title":"Potent Inhibitory Activities of the Adenosine Analogue Cordycepin on SARS-CoV-2 Replication","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"issue":"25","key":"10.1016\/j.compbiolchem.2022.107768_bib28","doi-asserted-by":"crossref","first-page":"21385","DOI":"10.1021\/acsomega.1c07095","article-title":"Efficacious Preclinical Repurposing of the Nucleoside Analogue Didanosine against COVID-19 Polymerase and Exonuclease","volume":"7","author":"Rabie","year":"2022","journal-title":"ACS Omega"},{"issue":"2","key":"10.1016\/j.compbiolchem.2022.107768_bib29","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1007\/s00044-022-02970-3","article-title":"Evaluation of a series of nucleoside analogs as effective anticoronaviral-2 drugs against the Omicron-B.1.1.529\/BA.2 subvariant: A repurposing research study","volume":"32","author":"Rabie","year":"2023","journal-title":"Med. Chem. Res."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.molliq.2022.118775","article-title":"Antiviral activities of 4H-chromen-4-one scaffold-containing flavonoids against SARS\u2013CoV\u20132 using computational and in vitro approaches","volume":"353","author":"Raj","year":"2022","journal-title":"J. Mol. Liq."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib31","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1016\/j.ijbiomac.2020.12.020","article-title":"Assessment of antiviral potencies of cannabinoids against SARS-CoV-2 using computational and in vitro approaches","volume":"168","author":"Raj","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"issue":"8","key":"10.1016\/j.compbiolchem.2022.107768_bib32","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003565","article-title":"Coronaviruses Lacking Exoribonuclease Activity Are Susceptible to Lethal Mutagenesis: Evidence for Proofreading and Potential Therapeutics","volume":"9","author":"Smith","year":"2013","journal-title":"PLoS Pathog."},{"issue":"8","key":"10.1016\/j.compbiolchem.2022.107768_bib33","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/S2213-2600(21)00222-8","article-title":"Colchicine for community-treated patients with COVID-19 (COLCORONA): a phase 3, randomised, double-blinded, adaptive, placebo-controlled, multicentre trial","volume":"9","author":"Tardif","year":"2021","journal-title":"Lancet Respir. Med."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib34","unstructured":"The Washington Post. Understanding omicron\u2019s many mutations. Available from: \u3008https:\/\/www.washingtonpost.com\/health\/2021\/12\/16\/omicron-variant-mutations-covid\u3009 (last Accessed 18 July 2022)."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib35","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1038\/s41421-020-0169-8","article-title":"The anti-influenza virus drug, arbidol is an efficient inhibitor of SARS-CoV-2 in vitro","volume":"6","author":"Wang","year":"2020","journal-title":"Cell Discovery"},{"key":"10.1016\/j.compbiolchem.2022.107768_bib36","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173634","article-title":"Tissue distributions of antiviral drugs affect their capabilities of reducing viral loads in COVID-19 treatment","volume":"889","author":"Wang","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib37","unstructured":"World Health Organization. Tracking SARS-CoV-2 variants. Available from: \u3008https:\/\/www.who.int\/en\/activities\/tracking-SARS-CoV-2-variants\u3009 (last Accessed\u00a027\u00a0July 2022)."},{"issue":"7","key":"10.1016\/j.compbiolchem.2022.107768_bib38","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1021\/acsmedchemlett.0c00316","article-title":"Advantages of the Parent Nucleoside GS-441524 over Remdesivir for Covid-19 Treatment","volume":"11","author":"Yan","year":"2020","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib39","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2021.105078","article-title":"A cell-based assay to discover inhibitors of SARS-CoV-2 RNA dependent RNA polymerase","volume":"190","author":"Zhao","year":"2021","journal-title":"Antiviral Res."},{"key":"10.1016\/j.compbiolchem.2022.107768_bib40","doi-asserted-by":"crossref","DOI":"10.1016\/j.antiviral.2022.105254","article-title":"5-Iodotubercidin inhibits SARS-CoV-2 RNA synthesis","volume":"198","author":"Zhao","year":"2022","journal-title":"Antiviral Res."}],"container-title":["Computational Biology and Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927122001487?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1476927122001487?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T13:30:52Z","timestamp":1761485452000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1476927122001487"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":40,"alternative-id":["S1476927122001487"],"URL":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2022.107768","relation":{},"ISSN":["1476-9271"],"issn-type":[{"value":"1476-9271","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Dual computational and biological assessment of some promising nucleoside analogs against the COVID-19-Omicron variant","name":"articletitle","label":"Article Title"},{"value":"Computational Biology and Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.compbiolchem.2022.107768","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107768"}}